ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’

Zevra's stock dropped 23% after the EMA's CHMP issued a negative opinion on arimoclomol for Niemann-Pick disease type C.

Arimoclomol is an experimental treatment for Niemann-Pick disease type C, a rare genetic disorder.

The negative CHMP opinion is a setback for Zevra's marketing application in the EU.

An analyst described the risk as 'a headwind, but not insurmountable,' suggesting possible recovery.

The negative opinion does not affect Zevra's ongoing regulatory processes in other regions.